Information  X 
Enter a valid email address

Feedback PLC (FDBK)

  Print          Annual reports

Tuesday 20 October, 2020

Feedback PLC

Bleepa adds 3D Imaging with Axial3D Partnership

RNS Number : 5367C
Feedback PLC
20 October 2020
 

 Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.

 

Feedback plc

 

Bleepa adds 3D imaging through partnership with Axial3D

 

· Enables clinicians to view and manipulate 3D clinical medical images to support clinical decision making and surgical planning

· Supports 3D model printing

· Suitable for complex surgical planning, patient education and consent and clinician training

 

London, 20 October 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces a commercial partnership with Axial Medical Printing Limited (trading as Axial3D (www.axial3d.com)) to enable the visualisation and use of 3D clinical-grade medical images from a patient's own 2D scan through Feedback's flagship medical imaging communications platform, Bleepa.

 

Axial3D uses advanced AI technologies to automatically segment imaging data and pull out isolated 3D reconstructions of individual organs or pathologies. These images will be available to view in the Bleepa platform and if required, can subsequently be turned into 3D printed models in a variety of materials. Axial3D's AI imaging technology will be integrated with Bleepa to enable the movement of users and DICOM (the standard format for medical images) between the two platforms, leveraging Bleepa's digital modular design to provide clinicians with 3D rendered images of specific pathologies or organs.  By partnering, frontline clinicians will be able to request Axial3D image renders from within Bleepa. The Bleepa user will be able to click through to Axial3D's system from Bleepa and the supporting DICOM study will be automatically pushed by Bleepa to Axial3D.  Axial3D will enter into its own commercial relationship with customers, but Bleepa will act as the user access point and will facilitate the data transfer on its behalf, with the customer's permission and following the agreed data processing arrangements between the customer and Axial3D. 

 

Increasingly, clinicians are looking to 3D imaging and 3D printed models of anatomical areas, created exactly from patients' 2D scans, which can be held in-hand and used for preoperative planning, simulation and collaborative team working.  These anatomical images and models are often used in patient communication and consultation to show and explain to patients their medical conditions and what their surgical procedures will involve.  3D anatomical models also have use in surgical education, providing medical students and junior doctors the opportunity to exactly see tumours, fractures, lesions and other abnormalities.

 

The commercial agreement will enable joint- and cross-selling of both products through each company's distribution channels to new and existing customers, enabling both organisations to grow collaboratively. Under the agreement Feedback will receive a commission for each user-generated image request from Axial3D. This is the first example of the Company's strategy to leverage its growing userbase to generate supplementary revenue, over and above the main user licence fee.

 

Dr Tom Oakley, CEO of Feedback, commented:

 

"The addition of 3D imaging and printing enhances our value proposition to Bleepa users and re-enforces our vision to bring clinicians together, armed with the tools and information they need to make better informed decisions faster. We are delighted to have Axial3D as such a dynamic and cutting-edge partner who share our vision and passion for supporting frontline clinicians. We hope that Bleepa will make Axial's technology even more accessible to a wider clinical userbase and that our partnership will help to drive the adoption of this key technology into the mainstream of frontline care. This important milestone confirms our strategy of becoming a gatekeeper platform for third-party technologies in order to generate additional revenues beyond the Bleepa user licence. We hope that this will be the first of many such partnerships."

 

Roger Johnston, CEO of Axial3D, said: 

 

"At Axial3D, we believe that the introduction of 3D imaging for planning complex surgeries can transform outcomes for patients, surgical teams and indeed hospitals. When surgeons use our models for surgical planning they tell us that in over 53% of cases they change their plan for surgery, compared to relying solely on the 2D MRI/CT scans. This leads to shorter surgeries, reduced costs of surgeries, reduced risk of patient infection with often less traumatic surgery, thus often leading to a shorter stay in hospital. Bleepa allows us to make available 3D imaging available as standard for clinical teams who are planning the surgeries, engaging with patients and their families, through to the surgeries themselves. We believe that Bleepa will transform surgical team collaboration across the NHS and beyond and Axial3D is delighted to be going on that journey with such a game-changing partner."

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

[email protected]

 

 

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

 

 

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey

+44 (0)20 7469 0936

 

 

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

+44 20 3815 8880

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go. 

 

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRUKVNRRUURAAA

a d v e r t i s e m e n t